FDAAA Impact Analysis (Year 7): The Era of the “Breakthrough” REMS
This article was originally published in RPM Report
Executive Summary
FDA continues to use the formal Risk Evaluation & Mitigation Strategy authority very infrequently in the context of new drug approvals. There is one countervailing trend: the agency is imposing mandatory communication plans for some of the new oncology therapies – including two “Breakthroughs.”